Immediate Impact

61 standout
Sub-graph 1 of 22

Citing Papers

Multifunctional nanoparticle-mediated combining therapy for human diseases
2024 Standout
Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations
2024 Standout
2 intermediate papers

Works of Andrea Ruzza being referenced

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia
2020
Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia
2017

Author Peers

Author Last Decade Papers Cites
Andrea Ruzza 794 268 213 45 936
Michel Zeitouni 529 686 58 65 1.1k
K Wenke 608 344 27 29 767
Gabriella Iannuzzo 393 328 40 70 916
Derek Connolly 389 291 171 43 799
Sara C. Martinez 532 404 29 31 1.1k
Fabrice Ivanés 234 551 35 49 967
Eralp Tutar 354 445 18 41 939
Anastasia Lesogor 616 526 153 23 1.1k
Ragnhild Wergeland 349 609 10 33 1.1k
Lung‐Chih Li 251 90 18 44 874

All Works

Loading papers...

Rankless by CCL
2026